Navigation Links
Doctor Declares War on Hospital Infections, Patents MRSA-Killing Machine
Date:9/10/2008

MEMPHIS, Tenn., Sept. 10 /PRNewswire/ -- As a surgeon and clinical instructor, Dr. Jeffery Deal, MD, FACS, DTMH, knew firsthand about the growing number of patients contracting ... and dying from ... Hospital Acquired Infections. He was also keenly aware that infections are quickly spreading beyond the healthcare system into schools, gyms, prisons and retirement homes.

A 2004 study supervised by Dr. Deal tracked 13,510 admissions at an accredited 450-bed regional hospital. Almost fifteen percent, 2,012 patients, acquired an infection. The average length of stay for infected patients increased 9.25 days, and direct hospital costs increased $13,118,000 -- over $29,000 per bed per year.

The CDC concedes that over two million people in the US will acquire an infection while in a hospital this year, and that more than 100,000 infected patients will die as a result. That's more deaths than are caused by murder, breast cancer and AIDS ... combined.

As infection rates continue to climb, industry experts predict a rash of lawsuits. "The common belief that 'infections are unavoidable' has shielded hospitals and doctors from liability for decades. But not in the future," states Dr. Betsy McCaughy, author of "Unnecessary Deaths: The Human and Financial Costs of Hospital Infections," 3rd edition.

Dr. Deal knew that reducing the biological pool of pathogens would reduce hospital infection. "Our goal was to find a disinfection method that was fast, safe and thorough; used no chemicals; and was automated to eliminate human error and reduce costs." After years of clinical trials, Dr. Deal applied for the first of two patents for the TRU-D Total Room Ultraviolet Disinfector. "Our research team developed a fail-safe disinfection method using germ-lethal doses of reflected UV germicidal energy to destroy virus, bacteria and spores within both line-of-site and primary shadow behind bed rails, door knobs and IV poles. TRU-D disinfected every pathogen on every surface, every time," said Deal.

Clinical trials demonstrated that TRU-D destroyed the biological contaminates that cause MRSA, C. diff, VRE, E. coli, acinetobactor, and a host of other infectious diseases. An unexpected benefit of TRU-D is that the air within the treated space is disinfected by default, preventing airborne pathogens from later re-colonizing sterile surfaces.

Dr. Deal licensed the worldwide distribution rights for the patented TRU-D Rapid Room Sterilizer to Lumalier Corporation of Memphis, Tennessee, a leader in Ultraviolet Germicidal Irradiation since 1963. Chuck Dunn, President of Lumalier, believes the timing for TRU-D is perfect. "While infection rates are rising at alarming rates, expanded Medicare rules will hold hospitals accountable and liable for acquired infections, costing millions of dollars in non-reimbursed funds. The requirement to publish individual hospital infection rates will expose quality of care issues to the public and provide a real choice to patients."

For more information about the Tru-D Rapid Room Sterilizer, call David Skelton @ 800-774-5799, or go to http://www.lumalier.com.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Lumalier Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
2. The ED Conversation Dilemma: Forty Percent of Men with ED Dont Talk to Their Doctor, Survey Finds
3. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
4. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
5. Arizona Doctor Offers New Addiction Drug Treatment for Meth Addicts Showing More Than 60% Success Rate
6. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
7. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
10. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
11. Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):